Is Exelixis Inc (EXEL) overvalued? · P/E 17, rev $2.17B
Exelixis Inc (EXEL) is a biotechnology company listed on US.
This page asks whether Exelixis Inc (EXEL) looks expensive on cached numbers — not a short thesis.
Latest reported EXEL revenue for 2025-01-03 was $2.17B. Net income was $521.3M. Revenue was up 18.5% from 2023-12-29 to 2025-01-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EXEL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EXEL stock page for the full model, not this heading.
Not investment advice.